Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multiple-dose pharmacokinetics and pharmacodynamics study of apixaban and rivaroxaban in healthy subjects
NL-OMON34739Active, not recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Jan 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Trial of apixaban and rivaroxaban in Phlebothrombosis and venous thromboembolism (VTE) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Multiple-dose pharmacokinetics of apixaban and rivaroxaban and Peak-to-trough plasma concentration ratio. Started Jan 2010; status: active, not recruiting.
02
Drugs
apixabanrivaroxaban
03
Conditions
Phlebothrombosisvenous thromboembolism (VTE)
Beyond the preview
Go deeper on NL-OMON34739.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON34739.